Literature DB >> 27125356

Definition of MYC genetic heteroclonality in diffuse large B-cell lymphoma with 8q24 rearrangement and its impact on protein expression.

Alexandra Valera1, Samantha Epistolio1, Lluis Colomo2, Alice Riva1, Olga Balagué3, Ivan Dlouhy3, Alexandar Tzankov4, Marco Bühler5, Eugenia Haralambieva5, Elias Campo3, Davide Soldini5, Luca Mazzucchelli1, Vittoria Martin1.   

Abstract

MYC rearrangement can be detected in a subgroup of diffuse large B-cell lymphoma characterized by unfavorable prognosis. In contrast to Burkitt lymphoma, the correlation between MYC rearrangement and MYC protein expression in diffuse large B-cell lymphoma is less clear, as approximately one-third of rearranged cases show negative or low expression by immunohistochemistry. To better understand whether specific characteristics of the MYC rearrangement may influence its protein expression, we investigated 43 de novo diffuse large B-cell lymphoma positive for 8q24 rearrangement by FISH, using 14 Burkitt lymphoma for comparison. Different cell populations (clones), breakpoints (classical vs non-classical FISH patterns), partner genes (IGH vs non-IGH) and immunostaining were detected and analyzed using computerized image systems. In a subgroup of diffuse large B-cell lymphoma, we observed different clones within the same tumor distinguishing the founder clone with MYC rearrangement alone from other subclones, carrying MYC rearrangement coupled with loss/extra copies of derivatives/normal alleles. This picture, which we defined MYC genetic heteroclonality, was found in 42% of cases and correlated to negative MYC expression (P=0.026). Non-classical FISH breakpoints were detected in 16% of diffuse large B-cell lymphoma without affecting expression (P=0.040). Non-IGH gene was the preferential partner of rearrangement in those diffuse large B-cell lymphoma showing MYC heteroclonality (P=0.016) and/or non-classical FISH breakpoints (P=0.058). MYC heteroclonality was not observed in Burkitt lymphoma and all cases had positive MYC expression. Non-classical FISH MYC breakpoint and non-IGH partner were found in 29 and 20% of Burkitt lymphoma, respectively. In conclusion, MYC genetic heteroclonality is a frequent event in diffuse large B-cell lymphoma and may have a relevant role in modulating MYC expression.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27125356     DOI: 10.1038/modpathol.2016.71

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  34 in total

1.  B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.

Authors:  Matija Snuderl; Olga K Kolman; Yi-Bin Chen; Jessie J Hsu; Adam M Ackerman; Paola Dal Cin; Judith A Ferry; Nancy Lee Harris; Robert P Hasserjian; Lawrence R Zukerberg; Jeremy S Abramson; Ephraim P Hochberg; Hang Lee; Alfred I Lee; Christiana E Toomey; Aliyah R Sohani
Journal:  Am J Surg Pathol       Date:  2010-03       Impact factor: 6.394

2.  B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.

Authors:  Shaoying Li; Pei Lin; Luis E Fayad; Patrick A Lennon; Roberto N Miranda; C Cameron Yin; E Lin; L Jeffrey Medeiros
Journal:  Mod Pathol       Date:  2011-10-14       Impact factor: 7.842

3.  MYC rearrangement and translocations involving band 8q24 in diffuse large cell lymphomas.

Authors:  M Ladanyi; K Offit; S C Jhanwar; D A Filippa; R S Chaganti
Journal:  Blood       Date:  1991-03-01       Impact factor: 22.113

Review 4.  FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue.

Authors:  Roland A Ventura; Jose I Martin-Subero; Margaret Jones; Joanna McParland; Stefan Gesk; David Y Mason; Reiner Siebert
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

5.  Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas.

Authors:  P Bertrand; C Bastard; C Maingonnat; F Jardin; C Maisonneuve; M-N Courel; P Ruminy; J-M Picquenot; H Tilly
Journal:  Leukemia       Date:  2007-01-18       Impact factor: 11.528

6.  BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome.

Authors:  Maria Grazia Tibiletti; Vittoria Martin; Barbara Bernasconi; Barbara Del Curto; Lorenza Pecciarini; Silvia Uccella; Giancarlo Pruneri; Maurillio Ponzoni; Luca Mazzucchelli; Giovanni Martinelli; Andrés J Ferreri; Graziella Pinotti; Andrea Assanelli; Marta Scandurra; Claudio Doglioni; Emanuele Zucca; Carlo Capella; Francesco Bertoni
Journal:  Hum Pathol       Date:  2009-01-13       Impact factor: 3.466

7.  MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

Authors:  Alexandra Valera; Armando López-Guillermo; Teresa Cardesa-Salzmann; Fina Climent; Eva González-Barca; Santiago Mercadal; Iñigo Espinosa; Silvana Novelli; Javier Briones; José L Mate; Olga Salamero; Juan M Sancho; Leonor Arenillas; Sergi Serrano; Nadina Erill; Daniel Martínez; Paola Castillo; Jordina Rovira; Antonio Martínez; Elias Campo; Luis Colomo
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

8.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors:  Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

9.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors:  Nathalie A Johnson; Graham W Slack; Kerry J Savage; Joseph M Connors; Susana Ben-Neriah; Sanja Rogic; David W Scott; King L Tan; Christian Steidl; Laurie H Sehn; Wing C Chan; Javeed Iqbal; Paul N Meyer; Georg Lenz; George Wright; Lisa M Rimsza; Carlo Valentino; Patrick Brunhoeber; Thomas M Grogan; Rita M Braziel; James R Cook; Raymond R Tubbs; Dennis D Weisenburger; Elias Campo; Andreas Rosenwald; German Ott; Jan Delabie; Christina Holcroft; Elaine S Jaffe; Louis M Staudt; Randy D Gascoyne
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544

10.  Interphase fluorescence in situ hybridization for detection of 8q24/MYC breakpoints on routine histologic sections: validation in Burkitt lymphomas from three geographic regions.

Authors:  Eugenia Haralambieva; Ed Schuuring; Stefano Rosati; Carel van Noesel; Patty Jansen; Inge Appel; Jeroen Guikema; Henry Wabinga; Luiz Fernando Bleggi-Torres; King Lam; Eva van den Berg; Clemens Mellink; Shama van Zelderen-Bhola; Philip Kluin
Journal:  Genes Chromosomes Cancer       Date:  2004-05       Impact factor: 5.006

View more
  2 in total

1.  IgA-producing lymphoplasmacytic lymphoma carrying the chromosomal abnormality t(8;14).

Authors:  Yuta Gotoh; Yumi Aoyama; Hiroko Tsunemine; Yuka Idei; Ayano Mori; Taiichi Kodaka; Sachiko Iba; Akihiro Tomita; Tomoo Itoh; Takayuki Takahashi
Journal:  J Clin Exp Hematop       Date:  2019-08-08

2.  Decreased CD11c-positive dendritic cells in the tumor microenvironment predict double-hit/triple-hit genotype and survival in diffuse large B-cell lymphoma.

Authors:  Chang-Tsu Yuan; Shih-Sung Chuang; Pei-Yuan Cheng; Koping Chang; Hsuan Wang; Jia-Huei Tsai; Jau-Yu Liau; Wen-Chien Chou
Journal:  J Pathol Clin Res       Date:  2022-06-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.